Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carlos H. dos Anjos"'
Autor:
Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment
Externí odkaz:
https://doaj.org/article/88f817264c2f476b8cdad0ce4fa3f038
Autor:
N. Ari Wijetunga, Carlos H. dos Anjos, W. Iris Zhi, Mark Robson, C. Jillian Tsai, Yoshiya Yamada, Laura Dover, Erin F. Gillespie, Amy J. Xu, Jonathan T. Yang
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5163-5174 (2021)
Abstract Purpose We examined the characteristics of breast cancer patients with oligometastases (OM) treated with stereotactic ablative body radiotherapy (SABR) to identify factors associated with local progression, distant metastasis progression, ti
Externí odkaz:
https://doaj.org/article/cd43f585124e4b7c9181d4a756d81078
Autor:
Leandro J. C. Oliveira, Aline B. L. Gongora, Felipe G. Barbosa, Carlos H. dos Anjos, Rodrigo R. Munhoz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Currently, there is no established standard of care for patients with metastatic CSCC. Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade. This case illustrates a patie
Externí odkaz:
https://doaj.org/article/38097a3f4f084b048ee5945faefafe29